Our vision
Predica Diagnostics B.V. is active in the field of diagnostics, prognostics and prediction of treatment response in oncology
Predica Diagnostics is a spin-off company of Radboudumc, incorporating over 20 years of cancer research experience.
Our Vision
No woman should have unjustified worries about getting cervical cancer and every cancer patient is taken care off with effective treatment protocols only. Predica Diagnostics has been founded based on the persuasion that further development of its technology can reach this goal.
Unmet Need
Cervical cancer is the fourth most common malignancy in women and fourth in mortality worldwide with 660,000 new cases and 350,000 deaths yearly. To reduce cervical cancer burden, national screening programs test for the presence of high risk human papilloma viruses (hrHPV, the causal agent of cervical cancer) in cervical scrapes. These tests have high sensitivity, but low clinical specificity, resulting in high rates of overdiagnosis and overtreatment.
All you need to know
Do you need more information or want to get in contact with us?
Get in contact here.